Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2).

Like Comment
The phase 3 reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) trials of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for psoriasis treatment are complete.We present 5-year pooled data from reSURFACE 1 and reSURFACE 2.reSURFACE 1 and reSURFACE 2 were double-blind, randomised, controlled studies with optional long-term extensions. Adults with moderate-to-severe chronic plaque psoriasis were randomised 2:2:1 to tildrakizumab 100 (TIL100) or 200 mg (TIL200) or placebo at weeks 0 and 4, and every 12 weeks thereafter (reSURFACE 2 included an etanercept arm). Efficacy outcomes included proportions of patients achieving absolute and relative improvement from baseline Psoriasis Area and Severity Index (PASI) score through week 244 in tildrakizumab responders (≥75% improvement from baseline PASI; PASI 75 response) continuously receiving the same dose and etanercept partial responders and nonresponders (PASI <75 response) switched to TIL200 at week 28. Safety was assessed from adverse events (AEs) in all patients as-treated.Efficacy analyses included 329 and 227 week 28 responders to TIL100 and TIL200, respectively, and 121 etanercept partial responders/nonresponders switched to TIL200 at week 28. Of TIL100 or TIL200 responders and etanercept partial responders/nonresponders entering the extensions, 235/302, 176/213, and 85/107, respectively, were evaluated at week 244, and 88·7%, 92·5%, and 81·3%, respectively, achieved PASI 75 response. Exposure-adjusted rates of serious AEs were 6·3 and 6·0 patients with events/100 patient-years of TIL100 and TIL200, respectively.Tildrakizumab treatment provided sustained disease control over 5 years in week 28 tildrakizumab responders and etanercept partial responders/nonresponders, with a reassuring safety profile.


View the full article @ The British journal of dermatology


Get PDF with LibKey

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
5122 Contributions
2 Followers
0 Following

No comments yet.